Eli Lilly and Co (BUE:LLY) Cyclically Adjusted FCF per Share: ARS133.14 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:LLY Eli Lilly and Co BUE:LLY
92 GF Score
Price ARS33,440.00
GF Value ARS43,312.22
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted FCF per Share?

Eli Lilly and Co BUE:LLY -0.54% 92 Cyclically Adjusted FCF per Share is ARS133.14 as of Jun. 2026. GuruFocus rates BUE:LLY with a GF Score™ of 92/100 and a GF Value™ of ARS43,312.22 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Eli Lilly and Co's adjusted free cash flow per share for the three months ended in Jun. 2026 was ARS29,667.152. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS133.14 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Eli Lilly and Co's average Cyclically Adjusted FCF Growth Rate was 41.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -1.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Eli Lilly and Co was 17.20% per year. The lowest was -6.20% per year. And the median was 4.80% per year.

As of today (2026-08-29), Eli Lilly and Co's current stock price is ARS33440.00. Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was ARS133.14. Eli Lilly and Co's Cyclically Adjusted Price-to-FCF of today is 251.16.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Eli Lilly and Co was 279.06. The lowest was 16.39. And the median was 59.85.


Eli Lilly and Co  (BUE:LLY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Eli Lilly and Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=33440.00/133.14
=251.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Eli Lilly and Co was 279.06. The lowest was 16.39. And the median was 59.85.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Eli Lilly and Co Cyclically Adjusted FCF per Share Related Terms


Eli Lilly and Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted FCF per Share Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 97.58 180.64 430.73 70.96 106.89

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.52 108.61 106.89 114.26 133.14

BUE:LLY vs JNJ, ABBV, MRK: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted Price-to-FCF falls into.


BUE:LLY
92GF Score
Eli Lilly and Co BUE:LLY
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eli Lilly and Co's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=29667.152/333.9520*333.9520
=29,667.152

Current CPI (Jun. 2026) = 333.9520.

Eli Lilly and Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 80.670 241.428 111.586
201612 91.879 241.432 127.088
201703 -38.584 243.801 -52.851
201706 89.186 244.955 121.589
201709 95.145 246.819 128.733
201712 91.478 246.524 123.920
201803 15.355 249.554 20.548
201806 -32.992 251.989 -43.723
201809 261.318 252.439 345.698
201812 121.835 251.233 161.949
201903 -14.190 254.202 -18.642
201906 148.099 256.143 193.087
201909 284.714 256.759 370.311
201912 427.559 256.974 555.637
202003 30.255 258.115 39.144
202006 592.894 257.797 768.039
202009 453.390 260.280 581.722
202012 354.493 260.474 454.493
202103 475.990 264.877 600.119
202106 517.852 271.696 636.512
202109 504.875 274.310 614.648
202112 768.995 278.802 921.110
202203 778.045 287.504 903.743
202206 197.081 296.311 222.117
202209 962.165 296.808 1,082.575
202212 758.873 296.797 853.874
202303 723.541 301.836 800.527
202306 -217.375 305.109 -237.924
202309 -2,818.424 307.789 -3,057.999
202312 -3,135.935 306.746 -3,414.068
202403 310.228 312.332 331.702
202406 251.160 314.175 266.970
202409 -1,927.887 315.301 -2,041.927
202412 3,248.729 315.605 3,437.587
202503 -7,580.391 319.799 -7,915.868
202506 6,771.372 322.561 7,010.498
202509 36,430.027 324.800 37,456.528
202512 1,643.329 324.054 1,693.523
202603 17,498.743 330.213 17,696.881
202606 29,667.152 333.952 29,667.152

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ARS133.14 mean?
Eli Lilly and Co (BUE:LLY) has a Cyclically Adjusted FCF per Share of ARS133.14 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Cyclically Adjusted FCF per Share too high?
Eli Lilly and Co's current Cyclically Adjusted FCF per Share is ARS133.14. Overall, Eli Lilly and Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Cyclically Adjusted FCF per Share compare to JNJ and ABBV?
Eli Lilly and Co's Cyclically Adjusted FCF per Share of ARS133.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Cyclically Adjusted FCF per Share is ARS133.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (BUE:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is ARS43,312.22, compared to a current price of ARS33,440.00 — trading 22.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is ARS133.14. Eli Lilly and Co's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Eli Lilly and Co (BUE:LLY), the current Cyclically Adjusted FCF per Share is ARS133.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (BUE:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of ARS33,440.00 is trading 22.8% below its estimated GF Value™ of ARS43,312.22. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for BUE:LLY:

  • Cyclically Adjusted FCF per Share: ARS133.14
  • GF Value™: ARS43,312.22 vs. price of ARS33,440.00 (22.8% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the BUE:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
92GF Score

Get the complete analysis for BUE:LLY

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS33,440.00
Price
ARS43,312.22
GF Value